Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3380183 | 0.99 | HTR2C (0.46) | HTR2CHTR2BNOTUM | |
| Hydrochloric Acid SCHEMBL6871211 | 0.88 | HTR6 (0.43) | HTR2CHTR2B | |
| SCHEMBL3381538 | 0.87 | OXTR (0.43) | — | |
| SCHEMBL3381685 | 0.84 | OXTR (0.41) | HTR2CHTR2BNOTUM | |
| SCHEMBL3377927 | 0.84 | OXTR (0.43) | HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7441572 | 0.83 | OXTR (0.40) | — | |
| SCHEMBL3381033 | 0.81 | OXTR (0.52) | HTR2CHTR2B | |
| SCHEMBL400825 | 0.81 | HTR6 (0.54) | NOTUM | |
| Hydrochloric Acid SCHEMBL2267895 | 0.80 | HTR6 (0.53) | NOTUM | |
| SCHEMBL4716706 | 0.80 | NOTUM (0.56) | HTR2CHTR2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | claimed |
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | JOVER ANTONI T | 2006-06-15 | — | — | US | claimed |
| US-7041665-B2 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-05-09 | — | — | US | claimed |
| EP-1500654-A1 | BENZOXAZINONE DERIVATIVES, THE PREPARATION AND USE THEREOF AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-26 | — | — | EP | claimed |
| US-20040067941-A1 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-04-08 | — | — | US | claimed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | disclosed |
| EP-1497285-B1 | BENZOXAZINONE-DERIVED COMPOUNDS, THEIR PREPARATION UND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2010-11-24 | — | — | EP | disclosed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| US-7514429-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2009-04-07 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | JOVER ANTONI T | 2006-06-15 | — | — | US | disclosed |
| US-7056914-B2 | Benzoxazinone-derived compounds, their preparation and use as medicaments | ESTEVE LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-06-06 | — | — | US | disclosed |
| US-7041665-B2 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-05-09 | — | — | US | disclosed |
| EP-1500654-B1 | BENZOXAZINONE DERIVATIVES, THE PREPARATION AND USE THEREOF AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2006-02-01 | — | — | EP | disclosed |
| EP-1500654-A1 | BENZOXAZINONE DERIVATIVES, THE PREPARATION AND USE THEREOF AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-26 | — | — | EP | disclosed |
| US-20040067941-A1 | Benzoxazinone derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-04-08 | — | — | US | disclosed |
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128701-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | XDH, CYP3A5, CYP4X1 | HTR2C 806/4885HTR2B 1326/4885NOTUM 1531/4885 |
| US-20040058920-A1 | Benzoxazinone-derived compounds, their preparation and use as medicaments | XDH, CYP3A5, CYP4X1 | HTR2C 806/4885HTR2B 1326/4885NOTUM 1531/4885 |
| US-20040067941-A1 | Benzoxazinone derivatives, their preparation and use as medicaments | XDH, CYP4X1, CYP3A5 | HTR2C 319/4885HTR2B 515/4885NOTUM 1220/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2B 31/4885NOTUM 1810/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | HTR2C 32/4885HTR2B 50/4885NOTUM 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.